PLX4032: does it keep its promise for metastatic melanoma treatment?

Bibliography

• How common is skin cancer? WHO, 2010. Available from: http://www.who.int/uv/faq/skincancer/en/index1.html [Last accessed on 21 June 2010]
   Google Scholar
• Linos E, Swetter SM, Cockburn MG, Increasing burden of melanoma in the United States. J Invest Dermatol 2009;129(7):1666-74
   PubMed Web of Science ®Google Scholar
• Cancer Facts and Figures 2010. American Cancer Society, 2010. Available from: http://www.cancer.org/downloads/STT/Cancer_Facts_and_Figures_2010.pdf [Last accessed on 21 June 2010]
   Google Scholar
• Balch CM, Gershenwald JE, Soong SJ, Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27(36):6199-206
   PubMed Web of Science ®Google Scholar
• Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004;351(10):998-1012
   PubMed Web of Science ®Google Scholar
• Tawbi HA, Kirkwood JM. Management of metastatic melanoma. Semin Oncol 2007;34(6):532-45
   PubMed Web of Science ®Google Scholar
• Nashan D, Muller ML, Grabbe S, Systemic therapy of disseminated malignant melanoma: an evidence-based overview of the state-of-the-art in daily routine. J Eur Acad Dermatol Venereol 2007;21(10):1305-18
   PubMed Web of Science ®Google Scholar
• Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 2000;19(1):21-34
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010. [Epub ahead of print]
   Google Scholar
• Garbe C, Schadendorf D, Stolz W, Short German guidelines: malignant melanoma. J Dtsch Dermatol Ges 2008;6(Suppl 1):S9-14
   PubMed Web of Science ®Google Scholar
• Bishop JA, Corrie PG, Evans J, UK guidelines for the management of cutaneous melanoma. Br J Plast Surg 2002;55(1):46-54
   PubMedGoogle Scholar
• Coit DG, Andtbacka R, Bichakjian CK, Melanoma. J Natl Compr Canc Netw 2009;7(3):250-75
   PubMed Web of Science ®Google Scholar
• Negrier S, Saiag P, Guillot B, Clinical practice guideline: 2005 update of recommendations for the management of patients with cutaneous melanoma without distant metastases (summary report). Bull Cancer 2006;93(4):371-84
   PubMed Web of Science ®Google Scholar
• Skalicky SE, Holt PE, Giblin M, Australian Cancer Network clinical practice guidelines for the management of ocular and periocular melanoma: an evidence-based literature analysis. Clin Experiment Ophthalmol 2008;36(7):646-58
   PubMed Web of Science ®Google Scholar
• Flaherty K, Puzanov I, Sosman J, Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol (Meeting Abstracts) 2009, 2009;27(15S): abstract. 9000
   PubMedGoogle Scholar
• Curtin JA, Fridlyand J, Kageshita T, Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353(20):2135-47
   PubMed Web of Science ®Google Scholar
• Meier F, Schittek B, Busch S, The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci 2005;10:2986-3001
   PubMed Web of Science ®Google Scholar
• Martin GS. Cell signaling and cancer. Cancer Cell 2003;4(3):167-74
   PubMedGoogle Scholar
• Sala E, Mologni L, Truffa S, BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res 2008;6(5):751-9
   PubMed Web of Science ®Google Scholar
• Zhuang L, Lee CS, Scolyer RA, Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma. J Clin Pathol 2005;58(11):1163-9
   PubMed Web of Science ®Google Scholar
• Zhang XD, Borrow JM, Zhang XY, Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria. Oncogene 2003;22(19):2869-81
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, Mutations of the BRAF gene in human cancer. Nature 2002;417(6892):949-54
   PubMed Web of Science ®Google Scholar
• Gorden A, Osman I, Gai W, Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res 2003;63(14):3955-7
   PubMed Web of Science ®Google Scholar
• Cohen Y, Rosenbaum E, Begum S, Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites. Clin Cancer Res 2004;10(10):3444-7
   PubMed Web of Science ®Google Scholar
• Brose MS, Volpe P, Feldman M, BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002;62(23):6997-7000
   PubMed Web of Science ®Google Scholar
• Wan PT, Garnett MJ, Roe SM, Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116(6):855-67
   PubMed Web of Science ®Google Scholar
• Bhatt KV, Spofford LS, Aram G, Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling. Oncogene 2005;24(21):3459-71
   PubMed Web of Science ®Google Scholar
• Wellbrock C, Rana S, Paterson H, Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS ONE 2008;3(7):e2734
   PubMed Web of Science ®Google Scholar
• Hoeflich KP, Gray DC, Eby MT, Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res 2006;66(2):999-1006
   PubMed Web of Science ®Google Scholar
• Sharma SV, Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 2007;21(24):3214-31
   PubMed Web of Science ®Google Scholar
• Weinstein IB, Joe A. Oncogene addiction (discussion 80). Cancer Res 2008;68(9):3077-80
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64(19):7099-109
   PubMed Web of Science ®Google Scholar
• Eisen T, Ahmad T, Flaherty KT, Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer 2006;95(5):581-6
   PubMed Web of Science ®Google Scholar
• Egberts F, Kahler KC, Livingstone E, Hauschild A. Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results. Onkologie 2008;31(7):398-403
   PubMed Web of Science ®Google Scholar
• Hauschild A, Agarwala SS, Trefzer U, Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009;27(17):2823-30
   PubMed Web of Science ®Google Scholar
• Schwartz GK, Robertson S, Shen A, A phase I study of XL281, a selective oral RAF kinase inhibitor in patients (Pts) with advanced solid tumors. J Clin Oncol 2009;27(15s Suppl): abstract 3513
   Google Scholar
• Ramurthy S, Subramanian S, Aikawa M, Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors. J Med Chem 2008;51(22):7049-52
   PubMed Web of Science ®Google Scholar
• Stuart DD, Aardalen KM, Lorenzana EG, Characterization of a novel Raf kinase inhibitor that causes target dependent tumor regression in human melanoma xenografts expressing mutant B-Raf. AACR Meeting Abstracts 2006;47(1140): abstract 4856
   Google Scholar
• Amiri P, Aikawa ME, Dove J, CHIR-265 is a potent selective inhibitor of c-Raf/B-Raf/mutB-Raf that effectively inhibits proliferation and survival of cancer cell lines with Ras/Raf pathway mutations. Proc Am Assoc Cancer Res 2006;47: abstract 4855
   Google Scholar
• Kefford R, Arkenau H, Brown MP, Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 2010;28(15 Suppl): abstract 8503
   Web of Science ®Google Scholar
• Adjei AA, Cohen RB, Franklin W, Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008;26(13):2139-46
   PubMed Web of Science ®Google Scholar
• Solit DB, Garraway LA, Pratilas CA, BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006;439(7074):358-62
   PubMed Web of Science ®Google Scholar
• Emery CM, Vijayendran KG, Zipser MC, MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA 2009;106(48):20411-16
   PubMed Web of Science ®Google Scholar
• Montagut C, Sharma SV, Shioda T, Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 2008;68(12):4853-61
   PubMed Web of Science ®Google Scholar
• Paraiso KH, Fedorenko IV, Cantini LP, Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer 2010;102(12):1724-30
   PubMed Web of Science ®Google Scholar
• Infante JR, Fecher LA, Nallapareddy S, Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212. J Clin Oncol 2010;28:7s(Suppl): abstract 2503
   Google Scholar
• Bollag G, Hirth P, Tsai J, Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma NatureYear published: (2010) DOI: doi:10.1038/nature09454; Sept 7 epub
   Google Scholar
• Tsai J, Lee JT, Wang W, Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 2008;105(8):3041-6
   PubMed Web of Science ®Google Scholar
• Khazak V, Astsaturov I, Serebriiskii IG, Golemis EA. Selective Raf inhibition in cancer therapy. Expert Opin Ther Targets 2007;11(12):1587-609
   PubMed Web of Science ®Google Scholar
• Smalley KS. PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma. Curr Opin Investig Drugs 2010;11(6):699-706
   PubMed Web of Science ®Google Scholar
• Tsai J, Zhang J, Bremer R, Development of a novel inhibitor of oncongenic B-Raf. Proc Am Assoc Cancer Res 2006;47(507): abstract 2412
   Google Scholar
• Sondergaard JN, Nazarian R, Wang Q, Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med 2010;8:39
   PubMed Web of Science ®Google Scholar
• Lee JTK, Smalley K, Tsai J, Anti-tumor activity of PLX4032, a novel BRaf V600E inhibitor. EJC Suppl 2006;4(12):569
   Google Scholar
• Su F, Yang HI, Higgin B, PLX4032, a selective beta-raf V600E inhibitor has potent anti-tumor activity in beta-raf V600E-bearing colorectal xenografts and shows additive effect with other chemoagents. AACR-NCI-EORTC Int Congress 2007;23: abstract 252
   Google Scholar
• Hersey P, Zhang X, Jiang C. Induction of apoptosis in human melanoma by the BRAF inhibitor PLX4032: the key to therapeutic success? J Clin Oncol 2010;28(7 Suppl): abstract 8559
   Google Scholar
• Halaban R, Zhang W, Bacchiocchi A, PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res 2010;23(2):190-200
   PubMed Web of Science ®Google Scholar
• Joseph D, Poulikakos PI, Pratilas CA, PLX4032, a selective inhibitor of RAF kinase activity, inhibits BRAF V600E tumor proliferation and MAPK signaling in vitro and in vivo. Am Assoc Cancer Res Ann Meeting 2008; 99th:abstract 3437
   Google Scholar
• Kaplan FM, Shao Y, Mayberry MM, Aplin AE. Hyperactivation of MEK–ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells. Oncogene, [6 September 2010] doi:10.1038/onc.2010.40 epub
   Google Scholar
• Montecillo ML, Sondergaard J, Ribas A. Antitumor activity of B-RAF inhibitor (PLX4032) against a panel of human melanoma cell lines. J Invest Med 2009;57(1 Suppl): abstract 403
   Web of Science ®Google Scholar
• Kolinsky K, Bollag G, Lee R, Antitumor activitiy of PLX4032, a selective V600E B-Raf inhibitor, as monotherapy and in combination with capecitabine + bevacizumab in a colorectal cancer xenograft model. EJC Suppl 2008;6(Suppl 12):185
   Web of Science ®Google Scholar
• Kolinsky K, Su F, Bollag G, Efficacy of PLX4032, a selective V600E B-Raf inhibitor, as monotherapy in combination with capecitabine +/- bevacizumab in a colorectal xenograft model. Gastrointestinal Cancers Symp 2009; abstract 362
   Google Scholar
• Nolop K, Jones WB, Tsai J, Discovery and pre-clinical development of a novel inhibitor of oncogenic B-Raf. J Clin Oncol 2006;24(Suppl 18S): abstract 13056
   Google Scholar
• Spevak W, Cho H, Shi S, Discovery and optimization of a selective inhibitor of oncogenic B-Raf. Am Chem Soc Natl Meet Exposition 2009; 237th(MEDI 086). Available from: http://wiz2.pharm.wayne.edu/mediabstracts2009.pdf
   Google Scholar
• Flaherty K, Puzanov I, Kim KB, “Inhibition of mutated, activated BRAF in metastatic melanoma” NEJM 2010;363(9):809-19
   Google Scholar
• Rubinstein JC, Sznol M, Pavlick AC, Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med 2010;8:67
   PubMed Web of Science ®Google Scholar
• McArthur G, Puzanov I, Ribas A, Early FDG-PET responses to PLX4032 in BRAF-mutant advanced melanoma. J Clin Oncol 2010;28(7 Suppl): abstract 8529
   Google Scholar
• Heidorn SJ, Milagre C, Whittaker S, Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010;140(2):209-21
   PubMed Web of Science ®Google Scholar
• Hatzivassiliou G, Song K, Yen I, RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010;464(7287):431-5
   PubMed Web of Science ®Google Scholar
• Poulikakos PI, Zhang C, Bollag G, RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010;464(7287):427-31
   PubMed Web of Science ®Google Scholar
• Cichowski K, Janne PA. Drug discovery: inhibitors that activate. Nature 2010;464(7287):358-9
   PubMed Web of Science ®Google Scholar
• Lacouture ME, McArthur G, Chapman PB, PLX4032 (RG7204), a selective mutant RAF inhibitor: clinical and histological characteristics of therapy-associated cutaneous neoplasms in a phase I trial. J Clin Oncol 2010;28(7 Suppl): abstract 8592
   PubMedGoogle Scholar
• Arnault JP, Wechsler J, Escudier B, Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol 2009;27(23):e59-61
   PubMed Web of Science ®Google Scholar
• Pratilas CA, Solit DB. Targeting the MAPK pathway: physiological feedback and drug response. Clin Cancer Res 2010;16(13):3329-34
   PubMed Web of Science ®Google Scholar
• Spencer JM, Kahn SM, Jiang W, Activated ras genes occur in human actinic keratoses, premalignant precursors to squamous cell carcinomas. Arch Dermatol 1995;131(7):796-800
   PubMed Web of Science ®Google Scholar
• Mateus C, Arnault J, Tomasic G, Activation of the MAP-kinase pathway in the skin of patients treated with sorafenib: clinical and molecular characterization of skin tumors associated with the multikinase inhibitor sorafenib. J Clin Oncol 2010;28(7 Suppl): abstract 9130
   Google Scholar
• Smalley KS, Nathanson KL, Flaherty KT. Genetic subgrouping of melanoma reveals new opportunities for targeted therapy. Cancer Res 2009;69(8):3241-4
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Smalley KS. Preclinical and clinical development of targeted therapy in melanoma: attention to schedule. Pigment Cell Melanoma Res 2009;22(5):529-31
   PubMed Web of Science ®Google Scholar